Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease ...

Organovo Holdings ( (ONVO) ) has issued an announcement.

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the medical research ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm specializing in biological products with a current market capitalization of $5.5 million, announced the appointment of Norman Staskey as its ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm specializing in biological products with a current market capitalization of $5.5 million, announced the appointment of Norman Staskey as ...

Organovo Holdings, Inc. appointed Norman Staskey as the new President, Chief Financial Officer, and Principal Financial Officer following the resignation of Tomas Hess, who left to pursue retirement.

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm specializing in biological products with a current market capitalization of $5.5 million, announced the appointment of... ByInvesting ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

( MENAFN - EIN Presswire) market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.